Study of Aztreonam for Inhalation in Children with Cystic Fibrosis and New Infection of the Airways by Pseudomonas aeruginosa bacteria

Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients with Cystic Fibrosis (CF) and New Onset Lower Respiratory Tract Culture Positive for Pseudomonas aeruginosa (PA) - ALPINE (Aztreonam Lysine for Pseudomonas Infection Eradication)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-001255-36-ES

Enrollment

Registered

2011-10-18

Start date

2011-11-23

Completion date

Unknown

Last updated

2021-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis and new onset lower respiratory tract culture positive for P.aeruginosa. MedDRA version: 14.0 Level: LLT Classification code 10068288 Term: Cystic fibrosis pulmonary exacerbation System Organ Class: 10021881 - Infections and infestations MedDRA version: 14.0 Level: PT Classification code 10070608 Term: Infective pulmonary exacerbation of cystic fibrosis System Organ Class: 10021881 - Infections and infestations

Interventions

Trade Name: Cayston Aztreonam 75 mg polvo y disolvente para solución para inhalación por nebulizador Product Name: Aztreonam for Inhalation Solution Product Code: AZLI Pharmaceutical Form: Powder and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Aged 3 months to less than 18 years. ? Diagnosis of CF as determined by the 1997 CF Consensus Conference criteria: sweat chloride level ? 60 mEq/L by quantitative pilocarpine iontophoresis; or a genotype with 2 identifiable mutations consistent with CF; or an abnormal nasal transepithelial potential difference (NPD), and 1 or more clinical features consistent with CF. ? Documented new onset of positive lower respiratory tract culture for PA within 30 days of study entry (screening visit) defined as either first lifetime documented PA-positive culture, or PA recovered after at least a 2-year history of PA-negative respiratory cultures (at least 2 cultures per year) ? FEV1 ? 80% predicted (for patients ? 6 years of age). ? Clinically stable with no evidence of significant respiratory symptoms or, if obtained for clinical evaluation, no chest radiograph findings at screening that would require administration of IV antipseudomonal antibiotics, oxygen supplementation, or hospitalization. Are the trial subjects under 18? yes Number of subjects for this age range: 80 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: ? Use of IV or inhaled antipseudomonal antibiotics within 2 years of study entry (screening visit). ? Use of oral antipseudomonal antibiotics within 30 days of study entry (screening visit). ? History of hypersensitivity/adverse reaction to aztreonam, or beta-agonists. ? Use of any investigational drug, or device within 28 days of study entry (screening visit). ? Presence of a condition or abnormality that would compromise the patient?s safety or the quality of study data, in the opinion of the investigator.

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate safety and efficacy of a 28-day course of AZLI in patients with initial PA pulmonary colonization/infection at Day 28 (end of treatment) and Days 56, 112, and 196 (1, 3, and 6 months after the end of treatment, respectively).;Secondary Objective: Below the age of 6 years pharmacokinetic data will be assessed.;Primary end point(s): The primary objective of this study is to evaluate the proportion of patients with PA-negative cultures at all time points during a 6-month monitoring period (through Day 196) after cessation of active treatment; microbiological cultures will be obtained at Baseline, Day 28 (end of treatment), Day 56 (1 month after completing AZLI), Day 112 (3 months after completing AZLI), and Day 196 (6 months after completing AZLI). PA-specific antibody titers will be obtained at Baseline, Day 28, and Day 196. Safety endpoints will include adverse events, airway reactivity (study drug-induced bronchspasm), vital signs, blood biochemistry and hematology.;Timepoint(s) of evaluation of this end point: Microbiological cultures will be obtained at Baseline (Day 1), Day 28 (end of treatment), Day 56 (1 month after completing AZLI), Day 112 (3 months after completing AZLI), and Day 196 (6 months after completing AZLI). PA-specific antibody titers will be obtained at Baseline, Day 28, and Day 196. Airway reactivity (study drug-induced bronchospasm) will be assessed at Baseline and Day 28. Blood biochemistry and hematology will be assessed at Screening, Baseline, Day 28 and Day 196. Adverse events and vital signs will be assessed at Screening, Baseline, Day 28, Day 56, Day 112 and Day 196.	—

Measure

Time frame

Main Objective: To evaluate safety and efficacy of a 28-day course of AZLI in patients with initial PA pulmonary colonization/infection at Day 28 (end of treatment) and Days 56, 112, and 196 (1, 3, and 6 months after the end of treatment, respectively).;Secondary Objective: Below the age of 6 years pharmacokinetic data will be assessed.;Primary end point(s): The primary objective of this study is to evaluate the proportion of patients with PA-negative cultures at all time points during a 6-month monitoring period (through Day 196) after cessation of active treatment; microbiological cultures will be obtained at Baseline, Day 28 (end of treatment), Day 56 (1 month after completing AZLI), Day 112 (3 months after completing AZLI), and Day 196 (6 months after completing AZLI). PA-specific antibody titers will be obtained at Baseline, Day 28, and Day 196. Safety endpoints will include adverse events, airway reactivity (study drug-induced bronchspasm), vital signs, blood biochemistry and hematology.;Timepoint(s) of evaluation of this end point: Microbiological cultures will be obtained at Baseline (Day 1), Day 28 (end of treatment), Day 56 (1 month after completing AZLI), Day 112 (3 months after completing AZLI), and Day 196 (6 months after completing AZLI). PA-specific antibody titers will be obtained at Baseline, Day 28, and Day 196. Airway reactivity (study drug-induced bronchospasm) will be assessed at Baseline and Day 28. Blood biochemistry and hematology will be assessed at Screening, Baseline, Day 28 and Day 196. Adverse events and vital signs will be assessed at Screening, Baseline, Day 28, Day 56, Day 112 and Day 196.

—

Secondary

Measure	Time frame
Secondary end point(s): In patients ? 6 years of age: ? Change from baseline in FEV1 % predicted at Days 28, 56, 112, and 196; ? Change from baseline in CFQ-R Respiratory Symptoms Score (RSS) at Days 28, 56, 112, and 196. In all patients: ? Proportion of patients with PA-negative cultures at Days 28, 56, 112 and 196; ? Use of additional (non-study) antipseudomonal antibiotics (as a marker for PA exacerbation); ? Change from baseline in weight, height, and body mass index (BMI) at Days 28, 56, 112, and 196; In patients < 6 years of age: ? Pharmacokinetics: 1 peak plasma sample will be obtained 1 hour after the first dose of AZLI (Day 1); 1 trough plasma sample will be obtained immediately prior to the last dose of AZLI (Day 28). Plasma aztreonam concentrations at each time point will be summarized (mean, median, standard deviation [SD], minimum, maximum, and number of samples).;Timepoint(s) of evaluation of this end point: In patients ? 6 years of age at Days 28, 56, 112, and 196: ? Change from baseline in FEV1 % predicted; ? Change from baseline in CFQ-R Respiratory Symptoms Score (RSS). In all patients at Days 28, 56, 112 and 196: ? Proportion of patients with PA-negative cultures; ? Change from baseline in weight, height, and body mass index (BMI). In all patients at Screening and Days 1, 28, 56, 112 and 196: ? Use of additional (non-study) antipseudomonal antibiotics (as a marker for PA exacerbation). In patients < 6 years of age: ? Pharmacokinetics: 1 peak plasma sample will be obtained 1 hour after the first dose of AZLI (Day 1); 1 trough plasma sample will be obtained immediately prior to the last dose of AZLI (Day 28).	—

Measure

Time frame

Secondary end point(s): In patients ? 6 years of age: ? Change from baseline in FEV1 % predicted at Days 28, 56, 112, and 196; ? Change from baseline in CFQ-R Respiratory Symptoms Score (RSS) at Days 28, 56, 112, and 196. In all patients: ? Proportion of patients with PA-negative cultures at Days 28, 56, 112 and 196; ? Use of additional (non-study) antipseudomonal antibiotics (as a marker for PA exacerbation); ? Change from baseline in weight, height, and body mass index (BMI) at Days 28, 56, 112, and 196; In patients < 6 years of age: ? Pharmacokinetics: 1 peak plasma sample will be obtained 1 hour after the first dose of AZLI (Day 1); 1 trough plasma sample will be obtained immediately prior to the last dose of AZLI (Day 28). Plasma aztreonam concentrations at each time point will be summarized (mean, median, standard deviation [SD], minimum, maximum, and number of samples).;Timepoint(s) of evaluation of this end point: In patients ? 6 years of age at Days 28, 56, 112, and 196: ? Change from baseline in FEV1 % predicted; ? Change from baseline in CFQ-R Respiratory Symptoms Score (RSS). In all patients at Days 28, 56, 112 and 196: ? Proportion of patients with PA-negative cultures; ? Change from baseline in weight, height, and body mass index (BMI). In all patients at Screening and Days 1, 28, 56, 112 and 196: ? Use of additional (non-study) antipseudomonal antibiotics (as a marker for PA exacerbation). In patients < 6 years of age: ? Pharmacokinetics: 1 peak plasma sample will be obtained 1 hour after the first dose of AZLI (Day 1); 1 trough plasma sample will be obtained immediately prior to the last dose of AZLI (Day 28).

—

Countries

Austria, Belgium, France, Germany, Ireland, Italy, Netherlands, Poland, Spain, United States

Contacts

Public ContactClinical Trials Information

Gilead Sciences International Limited

clinical.trials@gilead.com+441223897496

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026